Quarterly Activities/Appendix 4C Cash Flow Report
Filed with ASX ·
6ix is reading this filing.
Earlier from Imugene
- Further Responses in azer-cel Phase 1b Trial
- azer-cel BTKi Cohort Reports new Complete & Partial Response
- Third response in concurrent BTKi Cohort of azer-cel Trial
- $11.1 Million Placement Completed to Advance azer-cel
- New Complete Response in the Concurrent BTKi azer-cel Cohort
Follow Imugene into a list and get an email when it puts out news.
Follow Imugene